Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Sell
14
TOVX Quote, Financials, Valuation and Earnings
Last price:
$0.24
Seasonality move
:
13.43%
Day range:
$0.20 - $0.21
52-week range:
$0.20 - $2.08
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.33x
P/B ratio:
1.00x
Volume:
3.3M
Avg. volume:
22.5M
1-year change:
-84.61%
Market cap:
$6.8M
Revenue:
--
EPS (TTM):
-$5.54
Analysts' Opinion
-
Consensus RatingTheriva Biologics, Inc. has received a consensus rating of Leans Bullish. The company's average rating is a Leans Bullish based on 1 Buy rating, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $7.00, Theriva Biologics, Inc. has an estimated upside of 3398.25% from its current price of $0.20.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $7.00 representing 100% downside risk from its current price of $0.20.
Fair Value
-
According to the consensus of 2 analysts, Theriva Biologics, Inc. has 3398.25% upside to fair value with a price target of $7.00 per share.
TOVX vs. S&P 500
-
Over the past 5 trading days, Theriva Biologics, Inc. has underperformed the S&P 500 by -16.21% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Theriva Biologics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Theriva Biologics, Inc. revenues have been falling on a year-over-year basis for 4 quarters in a row. In the most recent quarter Theriva Biologics, Inc. reported revenues of --.
Earnings Growth
-
Theriva Biologics, Inc. has grown year-over-year earnings for 4 quarters straight. In the most recent quarter Theriva Biologics, Inc. reported earnings per share of -$0.45.
Enterprise value:
2M
EV / Invested capital:
0.21x
Price / LTM sales:
0.33x
EV / EBIT:
--
EV / Revenue:
-1.81x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-0.11x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$108K
Return On Assets:
-73.29%
Net Income Margin (TTM):
--
Return On Equity:
-171.04%
Return On Invested Capital:
-148.18%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -$404K | -$149K | -$108K | -$33K | -$28K | |
| Operating Income | -$20.2M | -$20.7M | -$17.2M | -$5M | -$4.4M | |
| EBITDA | -$19.8M | -$20.6M | -$17.1M | -$5M | -$4.4M | |
| Diluted EPS | -$29.51 | -$33.06 | -$5.54 | -$6.81 | -$0.45 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $73.6M | $52.7M | $34.8M | $19.5M | $9.9M | |
| Total Assets | $75.1M | $78.7M | $61.5M | $40.1M | $30.8M | |
| Current Liabilities | $3.2M | $13.2M | $8.7M | $7.3M | $11M | |
| Total Liabilities | $4.6M | $20.5M | $17.7M | $15.5M | $24.1M | |
| Total Equity | $70.6M | $58.1M | $43.9M | $24.6M | $6.7M | |
| Total Debt | $1.6M | $1.5M | $1.8M | $1.2M | $2.1M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$17.8M | -$18.8M | -$18.5M | -$3.9M | -$4.3M | |
| Cash From Investing | -$237K | -$57K | -$35K | -- | -$19K | |
| Cash From Financing | -$1.2M | $4M | $9.7M | $3.7M | -$148K | |
| Free Cash Flow | -$18.1M | -$18.8M | -$18.5M | -$3.9M | -$4.3M | |
TOVX
Sector
Market Cap
$6.8M
$28.4M
Price % of 52-Week High
9.62%
50.35%
Dividend Yield
0%
0%
Shareholder Yield
-171.67%
-1.32%
1-Year Price Total Return
-84.61%
-22.19%
Beta (5-Year)
0.342
0.521
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$0.23
200-day SMA
Sell
Level
$0.65
Bollinger Bands (100)
Sell
Level
0.3 - 0.48
Chaikin Money Flow
Sell
Level
-408.1M
20-day SMA
Sell
Level
$0.25
Relative Strength Index (RSI14)
Sell
Level
37.45
ADX Line
Buy
Level
34.64
Williams %R
Buy
Level
-97.7074
50-day SMA
Sell
Level
$0.34
MACD (12, 26)
Sell
Level
-0.03
25-day Aroon Oscillator
Sell
Level
-92
On Balance Volume
Neutral
Level
860.3M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-12.9532)
Sell
CA Score
(Annual)
Level (-1.7515)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (5.1467)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (1)
Sell
Fundamental Score
Level (1)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Theriva Biologics, Inc. is a clinical stage company, which engages in the development of therapeutics to preserve the microbiome to protect and restore the health of patients. Its product portfolio includes SYN-020 and SYN-004. SYN-020 is intended to prevent the antibiotic-mediated microbiome damage, C. difficile infections (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR) and acute graft-versus-host disease (aGVHD) in allogeneic HCT recipients. SYN-004 is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection, antibiotic-associated diarrhea, and the emergence of antimicrobial resistance. The company was founded by Steven H. Kanzer on January 8, 2001 and is headquartered in Rockville, MD.
Stock Forecast FAQ
In the current month, TOVX has received 1 Buy ratings 1 Hold ratings, and 0 Sell ratings. The TOVX average analyst price target in the past 3 months is $7.00.
-
Where Will Theriva Biologics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Theriva Biologics, Inc. share price will rise to $7.00 per share over the next 12 months.
-
What Do Analysts Say About Theriva Biologics, Inc.?
Analysts are divided on their view about Theriva Biologics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Theriva Biologics, Inc. is a Sell and believe this share price will drop from its current level to $7.00.
-
What Is Theriva Biologics, Inc.'s Price Target?
The price target for Theriva Biologics, Inc. over the next 1-year time period is forecast to be $7.00 according to 2 Wall Street analysts, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is TOVX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Theriva Biologics, Inc. is a Leans Bullish. 1 of 2 analysts rates the stock a Leans Bullish at this time.
-
How Can I Buy Shares Of TOVX?
You can purchase shares of Theriva Biologics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Theriva Biologics, Inc. shares.
-
What Is The Theriva Biologics, Inc. Share Price Today?
Theriva Biologics, Inc. was last trading at $0.24 per share. This represents the most recent stock quote for Theriva Biologics, Inc.. Yesterday, Theriva Biologics, Inc. closed at $0.20 per share.
-
How To Buy Theriva Biologics, Inc. Stock Online?
In order to purchase Theriva Biologics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get TOVX Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
TOVX
Sector
P/E ratio
--
23.66x
PEG ratio
--
-0.01x
P/B ratio
1.00x
1.84x
Price / LTM sales
0.33x
1.60x
Growth Metrics
TOVX
Sector
Revenue growth
--
4.85%
Earnings growth
93.38%
11.15%
Revenue (5-year growth)
--
6.45%
Earnings forecast
-$0.38
-$0.20
Profitability
TOVX
Sector
Profitability FY 2024
-$137K
$3.6M
Return on invested capital
-148.18%
-30.98%
Return on assets
-73.29%
-27.62%
Return on equity
-171.04%
-36.69%
Earnings Date
Last Earnings Date
Aug
14
Next Earnings Date
Dec
5
Estimated Next Earnings Date
Mar
6
Balance Sheet
TOVX
Sector
Total cash
$7.5M
$27.2M
Short term investments
--
$25.7M
Total assets
$39.7M
$79.9M
Long term debt
$2.1M
$4.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Buy
51
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 61x
Buy
65
Is AAPL Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 38x
Buy
69
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Sell
47
PSTG alert for Dec 4
Pure Storage, Inc. [PSTG] is up 5.05% over the past day.
Sell
41
SMX alert for Dec 4
SMX (Security Matters) Plc [SMX] is up 154.74% over the past day.
Sell
43
HY alert for Dec 4
Hyster-Yale, Inc. [HY] is up 1.92% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
